Search Results - "de Castro Carpeño, F.J."

An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer by Spicer, J., Provencio, M., Garrido Lopez, P., Bosch-Barrera, J., de Castro Carpeño, F.J., Felip, E., Trigo, J., Viteri, S., Coart, E., Schmidt, E., Christiansen, A.V., Zocca, M.-B., Andersen, M.H., Ehrnrooth, E., Paz-Ares, L.

Get full text

First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study by García de Paredes, M.L., del Moral González, F., Martínez del Prado, P., Martí Ciriquián, J.L., Enrech Francés, S., Cobo Dols, M., Esteban González, E., Ortega Granados, A.L., Majem Tarruella, M., Cumplido Burón, J.D., Gascó Hernández, A., López Miranda, E., Ciria Santos, J.P., de Castro Carpeño, F.J.

“…Thirty percent to ninety percent of cancer patients suffer from pain, including neuropathic pain (NP), which results in great burden for cancer patients. Thus,…”
Get full text